RECRUITING

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targeted cognitive training exercises and group support was developed to directly impact processing speed, and at the same time, boost motivation and engagement in adolescents at risk for schizophrenia and other psychotic disorders.

Official Title

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk in Adolescents at Clinical High Risk for Psychosis

Quick Facts

Study Start:2021-10-28
Study Completion:2026-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05131035

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:14 Years to 20 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Meet Clinical High Risk (CHR) criteria on the Structured Interview for Psychosis Risk Syndromes, defined by the presence of at least one attenuated positive symptom at a moderate to severe level
  2. * A score representing 0.5 SD below the mean on Animal Naming, Trails A or BACS: Symbol Coding from the MATRICS Consensus Cognitive Battery (MCCB).
  1. * Any DSM 5 Schizophrenia-Spectrum diagnosis
  2. * Non-English speaking
  3. * Past or current history of a clinically significant central nervous system disorder (e.g., seizure disorder)
  4. * Estimated IQ\<70
  5. * Significant head injury
  6. * Significant substance abuse
  7. * Significant visual or auditory impairment.

Contacts and Locations

Study Contact

Ricardo E Carrion, Ph.D.
CONTACT
718-470-8788
rcarrion@northwell.edu
Danielle McLaughlin, M.A.
CONTACT
718-470-8375
dmclaugh@northwell.edu

Principal Investigator

Barbara A Cornblatt, Ph.D.
PRINCIPAL_INVESTIGATOR
Northwell Health

Study Locations (Sites)

Northwell Health- The Zucker Hillside Hospital
Glen Oaks, New York, 11042
United States

Collaborators and Investigators

Sponsor: Northwell Health

  • Barbara A Cornblatt, Ph.D., PRINCIPAL_INVESTIGATOR, Northwell Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-10-28
Study Completion Date2026-05-31

Study Record Updates

Study Start Date2021-10-28
Study Completion Date2026-05-31

Terms related to this study

Keywords Provided by Researchers

  • Clinical High Risk (CHR)
  • Processing Speed
  • Social Functioning
  • Social Impairment
  • Social Skills
  • Adolescents
  • Cognitive Remediation

Additional Relevant MeSH Terms

  • Psychosis
  • Prodromal Schizophrenia
  • Prodromal Symptoms